Mechanisms of efficacy and toxicity after AAV gene therapy for DMD
Active Project Grant Awarded Last action
- Award ID
- HT9425261E406
- Recipient
-
The Children's Hospital Of Philadelphia UEI G7MQPLSUX1L4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,749,980
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 3% complete
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded $1,749,980 to The Children's Hospital of Philadelphia on September 1, 2026, to investigate mechanisms of efficacy and toxicity following adeno-associated virus gene therapy for Duchenne muscular dystrophy. The award, made under the Military Medical Research and Development program (CFDA 12.420), runs through August 31, 2030, with work performed in Philadelphia, PA. The Children's Hospital of Philadelphia Research Institute, operating as Children's Hospital of Philadelphia Foundation, is the recipient organization. This project grant supports basic and applied biomedical research to advance medical solutions and transform health care for Service Members and the American public through innovative investigation aligned with Defense Health Agency priorities.
Quick answers
Who received award HT9425261E406?
HT9425261E406 was awarded to The Children's Hospital Of Philadelphia by Defense Health Agency (Department of Defense) on September 1, 2026.
How much is award HT9425261E406 worth?
$1,749,980 has been obligated on HT9425261E406.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award